Home / Pharmaceutical / The Pharmaceutical Market: Slovakia

The Pharmaceutical Market: Slovakia

Published: Jul 2014 | No Of Pages: 114 | Published By: Espicom

Product Synopsis

 
OVERVIEW OF THE PHARMACEUTICAL MARKET IN SLOVAKIA
 
Slovak Prime Minister Robert Fico plans to unify the country'sprivate and public health insurance funds into a single state-owned insurer, but there is likely to be a lengthy negotiation and a legal battle before this is realised. We do not expect either of the two private insurers - Dôvera or Dutch-owned Union - will surrender their businesses without a fight, with Union in particular well-placed toopposethe move, potentially invoking EU law on protectionism. The outcome of thissteptowards a single insurer is broadly neutral for BMI's healthcare expenditure projections and is unlikely to have any meaningful impact until 2014 at the earliest, after which it would be negative for private healthcare providers.
 
Headline Expenditure Projections
 
  • Pharmaceuticals: EUR1.72bn (US$2.39bn) in 2011 to EUR1.65bn (US$2.10bn) in 2012; -3.8% in local currency terms and -12.1% in US dollar terms. Local currency forecast broadly unchanged from Q4 12.
  • Healthcare: EUR5.92bn (US$8.23bn) in 2011 to EUR6.03bn (US$7.65bn) in 2012; +1.7% in local currency terms and -7.0% in US dollar terms. Local currency forecastslightly lowerfrom Q4 12, on account of new historical trends.
  • Medical devices: EUR396mn (US$550mn) in 2011 to EUR396mn (US$503) in 2012; +0.2% in local currency terms and -8.4% in US dollar terms. Local currency forecastconsiderably lowerfrom Q4 12, on account of new historical data.
Competitive Landscape
 
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
BMI Industry View7
SWOT9
Political11
Economic12
Business Environment13
Industry Forecast14
Pharmaceutical Market Forecast14
 
Table: Pharmaceutical Sales, Historical Data And Forecasts (Slovakia 2010-2018)15
 
Healthcare Market Forecast16
 
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Slovakia 2010-2018)17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Slovakia 2010-2018)18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Slovakia 2010-2018)18
 
Prescription Drug Market Forecast19
 
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Slovakia 2010-2018)21
 
Patented Drug Market Forecast22
 
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Slovakia 2010-2018)23
 
Generic Drug24
 
Table: Members Of GENAS, 201126
Table: Generics Drug Market Indicators, Historical Data And Forecasts (Slovakia 2010-2018)26
 
OTC Medicine Market Forecast27
 
Table: Leading Prescription Medicines In Slovakia, By 2011 Volume28
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Slovakia 2010-2018)29
 
Pharmaceutical Trade Forecast30
 
Table: Pharmaceutical Trade Data And Forecasts (Slovakia 2012-2018)32
Table: Pharmaceutical Trade Data And Forecasts local currency (Slovakia 2012-2018)32
 
Other Healthcare Data33
Key Risks To BMI's Forecast Scenario33
Macroeconomic Forecasts35
 
Table: Slovakia - GDP By Expenditure39
 
Industry Risk Reward Ratings40
Central And Eastern Europe Risk/Reward Ratings40
Slovakia Risk/Reward Ratings47
Rewards47
Risks47
Market Overview50
Industry Trends And Developments51
Epidemiology51
 
Table: Main Causes Of Mortality And Morbidity In Slovakia52
 
Communicable Diseases52
Healthcare Sector53
Recent Healthcare Sector Developments54
Health Insurance56
Private Health Insurance57
Recent Health Insurance Developments58
Research And Development60
 
Table: Members Of BITCET, 201161
Table: Members Of SLOVBIOTECH, 201062
 
Clinical Trials62
Regulatory Development64
Regulatory Regime64
Pharmaceutical Promotion And Advertising65
Marketing Authorisation Regime66
Intellectual Property Regime67
Pricing Regime68
 
Table: Indexed Price Build-Up For Prescription And Non-Prescription Medicines In Slovakia69
 
Reimbursement Regime70
Competitive Landscape74
Pharmaceutical Industry74
 
Table: Registered Pharmaceutical Manufacturers74
Table: Members Of SAFS, 201275
 
Pharmaceutical Distribution76
 
Table: ADL Members, 2012 (Manufacturers, unless otherwise indicated)76
 
Pharmaceutical Retail77
Company Profile79
Roche79
Biotika81
HBM Pharma84
Imuna Pharma87
GlaxoSmithKline89
Sanofi91
Pfizer94
Novartis96
Merck & Co98
Zentiva (Sanofi)100
Demographic Forecast103
Demographic Outlook103
 
Table: Slovakia's Population By Age Group, 1990-2020 ('000)104
Table: Slovakia's Population By Age Group, 1990-2020 (% of total)105
Table: Slovakia's Key Population Ratios, 1990-2020106
Table: Slovakia's Rural And Urban Population, 1990-2020106
 
Glossary107
Methodology109
Pharmaceutical Expenditure Forecast Model109
Healthcare Expenditure Forecast Model109
Notes On Methodology110
Risk/Reward Ratings Methodology111
Ratings Overview112
 
Table: Pharmaceutical Risk/Reward Ratings Indicators112
 
Indicator Weightings113
Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +